COVID-19 Coagulopathy: Whom to Anticoagulate and How? What Agents to…

Rush University Medical Center

S. Jain

Role of Anticoagulants and Antiplatelet Agents for Patients With COV…

CHEST 2022 Coverage

V. Balasubramanian

How do I Recognize and Treat the VEXAS Syndrome?

Cleveland Clinic Rheumatology

P. Grayson

Walking Pneumonia, the Beginning of Influenza Season, and Does Antiv…

MicrobeTV

D. Griffin, V. Racaniello

Updates in Thrombosis and Anticoagulation

Fred Hutch 14th Annual Comprehensive Hematology & Oncology Review Course

D. Garcia

What to Know About the FDA Authorization and Approval of Updated COV…

Amesh Adalja

Preparing for Winter: CDC Recommendations for Influenza, COVID-19, a…

Diego Hijano

Project 2025 vs. the Public's Health Part II: The FDA

MicrobeTV

P. Offit, V. Racaniello

Five Things Every Internist Should Know About Anticoagulants

McMaster University Department of Medicine

S. Mithoowani

What's New with COVID in 2024?

Michigan Medicine

L. Washer

Management of Simultaneous Venous and Arterial Thromboembolic Disease

Scripps Health

J. May

Diagnosis and Goals of Therapy in PV

Northwestern Medicine Oncology and Hematology

B. Stein

Current Review of Benign Hematology and Coagulopathy

Indy Hematology Review

C. Kessler

Perioperative Considerations for Anticoagulation With Mechanical Dev…

James Douketis

Venous Thromboembolism Prophylaxis in Newly Diagnosed MM

Vanderbilt University Medical Center (VUMC)

M. Baljevic

ACAAI 2024 Insights: Secondary Immunodeficiency - Management Strateg…

ACAAI 2024 Insights

S. Mustafa

2023 ISTH Insights: "The EVE Trial - Extending VTE Secondary Prevent…

Robert McBane

Polycythemia Vera: Disease Overview, Treatment Landscape, and Curren…

Jerry Spivak

Fred Hutchinson Cancer Center Update in Thromboembolism

Fred Hutch 13th Annual Comprehensive Hematology & Oncology Review Course

D. Garcia

EHA 2024 Insights: Low-Molecular-Weight Heparin and VTE in Newly Dia…

Insights from 2024 EHA Annual Meeting

M. Lauw